Ran Reshef
Ran Reshef
Columbia University Medical Center
Potvrđena adresa e-pošte na
International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium
AC Harris, R Young, S Devine, WJ Hogan, F Ayuk, U Bunworasate, ...
Biology of Blood and Marrow Transplantation 22 (1), 4-10, 2016
Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis
E Lefebvre, G Moyle, R Reshef, LP Richman, M Thompson, F Hong, ...
PloS one 11 (6), e0158156, 2016
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease
R Reshef, SM Luger, EO Hexner, AW Loren, NV Frey, SD Nasta, ...
New England Journal of Medicine 367 (2), 135-145, 2012
Prospective, randomized, double-blind, phase III clinical trial of anti–T-lymphocyte globulin to assess impact on chronic graft-versus-host disease–free survival in patients …
RJ Soiffer, HT Kim, J McGuirk, ME Horwitz, L Johnston, MM Patnaik, ...
Journal of Clinical Oncology 35 (36), 4003, 2017
Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder★
R Reshef, S Vardhanabhuti, MR Luskin, DF Heitjan, D Hadjiliadis, S Goral, ...
American Journal of Transplantation 11 (2), 336-347, 2011
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
MJ Hartwell, U Özbek, E Holler, AS Renteria, H Major-Monfried, P Reddy, ...
JCI insight 2 (3), 2017
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
CA Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ...
The lancet oncology 23 (1), 91-103, 2022
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc …
J Bolaños-Meade, R Reshef, R Fraser, M Fei, S Abhyankar, Z Al-Kadhimi, ...
The Lancet Haematology 6 (3), e132-e143, 2019
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
H Major-Monfried, AS Renteria, A Pawarode, P Reddy, F Ayuk, E Holler, ...
Blood, The Journal of the American Society of Hematology 131 (25), 2846-2855, 2018
The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder
MR Luskin, DS Heil, KS Tan, S Choi, EA Stadtmauer, SJ Schuster, ...
American Journal of Transplantation 15 (10), 2665-2673, 2015
Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL)
C Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ...
Blood 136, 40-41, 2020
Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity
S He, Y Liu, L Meng, H Sun, Y Wang, Y Ji, J Purushe, P Chen, C Li, ...
Nature communications 8 (1), 2125, 2017
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis
M Gooptu, R Romee, A St. Martin, M Arora, M Al Malki, JH Antin, ...
Blood, The Journal of the American Society of Hematology 138 (3), 273-282, 2021
Pediatric‐inspired therapy compared to allografting for P hiladelphia chromosome‐negative adult ALL in first complete remission
MD Seftel, D Neuberg, MJ Zhang, HL Wang, KK Ballen, J Bergeron, ...
American journal of hematology 91 (3), 322-329, 2016
COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ...
Blood cancer discovery 1 (3), 234-243, 2020
Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide
SR McCurdy, MJ Zhang, A St. Martin, MM Al Malki, A Bashey, S Gaballa, ...
Blood advances 2 (3), 299-307, 2018
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis
RH Moy, AP Huffman, LP Richman, L Crisalli, XK Wang, JA Hoxie, R Mick, ...
Blood, The Journal of the American Society of Hematology 129 (7), 906-916, 2017
Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
BC Shaffer, KW Ahn, ZH Hu, T Nishihori, AK Malone, D Valcárcel, ...
Journal of Clinical Oncology 34 (16), 1864, 2016
Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning
R Reshef, EO Hexner, AW Loren, NV Frey, EA Stadtmauer, SM Luger, ...
Biology of Blood and Marrow Transplantation 20 (11), 1758-1766, 2014
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
HK Srinagesh, U Özbek, U Kapoor, F Ayuk, M Aziz, K Ben-David, ...
Blood advances 3 (23), 4034-4042, 2019
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20